Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

5.77
BATS BZX Real-Time Price
As of 10:44am ET
 -0.21 / -3.51%
Today’s Change
3.10
Today|||52-Week Range
7.84
-23.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$416.4M

Company Description

PProgenics Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Its pipeline candidates include PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC) directed toward PSMA and designed to deliver targeted chemotherapy to cancer cells, and MIP-1404, an imaging agent candidate with potential to alter clinical practice in treating prostate cancer. Its principal programs are directed toward gastroenterology, oncology and virology. Progenics Pharmaceuticals was founded by Paul J. Maddon on December 1, 1986 and is headquartered in Tarrytown, NY.

Contact Information

Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591
P:(914) 789-2800
Investor Relations:

Employees

Shareholders

Mutual fund holders46.85%
Other institutional42.90%
Individual stakeholders15.26%

Top Executives

Mark Robert BakerPresident, Chief Executive Officer & Director
Angelo William LovalloChief Financial Officer, Treasurer, CAO & VP
Robert J. IsraelExecutive Vice President-Medical Affairs
John W. BabichSenior Vice President
Nitya G. RaySenior Vice President-Manufacturing

To view my watchlist

Not a member yet?

Sign up now for a free account